Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nexalin Technology Inc (NXLIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NXLIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 15.71% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 4.05 | 52 Weeks Range 0.05 - 0.78 | Updated Date 06/17/2025 |
52 Weeks Range 0.05 - 0.78 | Updated Date 06/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4903.63% |
Management Effectiveness
Return on Assets (TTM) -189.48% | Return on Equity (TTM) -367.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 14715129 |
Shares Outstanding - | Shares Floating 14715129 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Nexalin Technology Inc
Company Overview
History and Background
Nexalin Technology, Inc. is a neurostimulation company developing and commercializing non-invasive neurostimulation devices to provide relief to those suffering from mental health conditions, including anxiety and depression. The company was incorporated in 2010.
Core Business Areas
- Neurostimulation Devices: Development and commercialization of non-invasive neurostimulation devices to treat mental health conditions.
Leadership and Structure
The leadership team includes individuals with experience in medical device development, regulatory affairs, and commercialization. Detailed organizational structure is not publicly available.
Top Products and Market Share
Key Offerings
- Gen-1 Device: Nexalin's original device. No specific market share data available. Competitors include TMS and ECT therapies, as well as other neurostimulation devices from companies like Neuronetics (STIM).
- Gen-2 Device: Nexalin's second-generation neurostimulation device, designed to be more efficient and user-friendly. No specific market share data available. Competitors include TMS and ECT therapies, as well as other neurostimulation devices from companies like Neuronetics (STIM).
Market Dynamics
Industry Overview
The neurostimulation market is growing due to increasing awareness of mental health conditions and demand for non-invasive treatments. The market includes various technologies, such as TMS, ECT, and tDCS.
Positioning
Nexalin is positioned as a provider of non-invasive neurostimulation therapy, targeting the anxiety and depression markets. Competitive advantages include the device's safety profile and potential efficacy.
Total Addressable Market (TAM)
The global market for neurostimulation devices is estimated to be in the billions of dollars. Nexalin is positioned to capture a portion of this TAM with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Non-invasive treatment approach
- Potential for reduced side effects compared to medication
- Innovative technology
Weaknesses
- Limited clinical trial data
- Small market capitalization
- Relatively new to the market
Opportunities
- Expanding into new mental health indications
- Securing partnerships with healthcare providers
- Gaining regulatory approvals in new markets
Threats
- Competition from established neurostimulation technologies
- Regulatory hurdles
- Limited market adoption
Competitors and Market Share
Key Competitors
- Neuronetics (STIM)
- Magstim
- Brainsway (BWAY)
Competitive Landscape
Nexalin competes with established neurostimulation companies. Its advantages include a unique technology, while disadvantages include limited clinical data and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to determine due to the company's early stage.
Future Projections: Future growth projections depend on clinical trial results, regulatory approvals, and market adoption. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include pursuing clinical trials and securing regulatory approvals.
Summary
Nexalin Technology Inc. is an early-stage company with a promising non-invasive neurostimulation technology. However, it faces challenges related to limited clinical data, small market capitalization, and competition from established players. Success hinges on positive clinical trial results, successful commercialization, and securing regulatory approvals. The company needs to increase its market share and prove the long-term efficacy of its devices to become a significant player in the neurostimulation market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexalin Technology Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO, CFO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com | ||
Nexalin Technology, Inc. designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy. It also offers Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. The company was incorporated in 2010 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.